NASDAQ: MTEMMolecular Templates Inc Stock
$1.78-0.11 (-5.82%)
Updated Apr 15, 2024
MTEM Price
$1.78
Fair Value Price
N/A
Market Cap
$9.57M
52 Week Low
$1.68
52 Week High
$9.45
P/E
0.99x
P/B
2.27x
P/S
0.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$57.31M
Earnings
-$8.12M
Gross Margin
100%
Operating Margin
-9.56%
Profit Margin
-14.2%
Debt to Equity
7.4
Operating Cash Flow
-$42M
Beta
1.13
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MTEM Overview
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MTEM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTEM was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MTEM is good value based on its earnings relative to its share price (0.99x), compared to the US market average (41.94x)
P/E vs Market Valuation
MTEM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more MTEM due diligence checks available for Premium users.
Be the first to know about important MTEM news, forecast changes, insider trades & much more!
MTEM News
Valuation
MTEM fair value
Fair Value of MTEM stock based on Discounted Cash Flow (DCF)
Price
$1.78
Fair Value
$158.56
Undervalued by
98.88%
MTEM was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MTEM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.99x
Industry
14.94x
Market
41.94x
MTEM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MTEM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MTEM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.27x
Industry
5.88x
MTEM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MTEM's financial health
Profit margin
Revenue
$7.0M
Net Income
-$3.9M
Profit Margin
-56.3%
MTEM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MTEM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$35.4M
Liabilities
$31.2M
Debt to equity
7.4
MTEM's short-term liabilities ($17.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTEM's short-term assets ($16.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTEM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MTEM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.3M
Investing
-$1.0k
Financing
$0.0
MTEM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTEM vs Biotech Stocks
Molecular Templates Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.